1665 related articles for article (PubMed ID: 15698733)
1. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
3. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
Zhao XW; Jiang B; Han CZ; Jing JX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
[TBL] [Abstract][Full Text] [Related]
4. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
5. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
[TBL] [Abstract][Full Text] [Related]
6. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
Tao LY; Cai L; He XD; Liu W; Qu Q
Am Surg; 2010 Nov; 76(11):1210-3. PubMed ID: 21140686
[TBL] [Abstract][Full Text] [Related]
7. Tumor markers in staging and prognosis of colorectal carcinoma.
Levy M; Visokai V; Lipska L; Topolcan O
Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
[TBL] [Abstract][Full Text] [Related]
8. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
9. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
10. [Clinical value of serum CEA, CA19-9, CA72-4 and CA242 in the diagnosis and prognosis of gastric cancer].
Zhu YB; Ge SH; Zhang LH; Wang XH; Xing XF; DU H; Hu Y; Li YA; Jia YN; Lin Y; Fan B; Ji JF
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):161-4. PubMed ID: 22368025
[TBL] [Abstract][Full Text] [Related]
11. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
12. Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement.
Yang XQ; Yan L; Chen C; Hou JX; Li Y
Hepatogastroenterology; 2009; 56(94-95):1388-94. PubMed ID: 19950797
[TBL] [Abstract][Full Text] [Related]
13. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
14. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
15. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
Huang C; Bei L; Liu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH
Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811
[TBL] [Abstract][Full Text] [Related]
17. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
Pasanen PA; Kauppinen R; Eskelinen M; Partanen K; Pikkarainen P; Alhava E
Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910
[TBL] [Abstract][Full Text] [Related]
18. [Significance of CEA and CA242 in the diagnosis of colorectal carcinoma].
Wu J; Yu H; Shao Y
Zhonghua Zhong Liu Za Zhi; 1995 Nov; 17(6):438-40. PubMed ID: 8697997
[TBL] [Abstract][Full Text] [Related]
19. The use of tumor markers as predictors of prognosis in gastric cancer.
Mihmanli M; Dilege E; Demir U; Coskun H; Eroglu T; Uysalol MD
Hepatogastroenterology; 2004; 51(59):1544-7. PubMed ID: 15362797
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
